scholarly journals Antipsychotics and mortality among elderly with dementia: a population based study in the Lazio region

2020 ◽  
Vol 30 (Supplement_5) ◽  
Author(s):  
A M Bargagli ◽  
S Cascini ◽  
N Agabiti ◽  
U Kirchmayer ◽  
C Marino ◽  
...  

Abstract Background Most dementia patients experience one or more behavioral and psychological symptoms (BPSD) at some time during their illness, in particular in the middle and later stages. Antipsychotic drugs (AP) are often prescribed off-label for treating BPSD, despite concerns about safety and limited efficacy. The impact of AP on short- and long-term mortality has not been fully assessed. Objective To assess the association between the use of APs and short- and long-term mortality in a cohort of dementia patients aged ≥ 65 years residing in the Lazio region. Methods We use data from regional health information systems to conduct a retrospective age, gender and comorbidity matched cohort study with a 1:3 matching ratio to pair dementia patients new AP users with non-users. For the exposed participants, the index date was defined as the date of the first drug prescription; the same date was used for non-users matched subjects. Patients were enrolled on 31/12/2016 and followed-up from the index date through 2018. Four cohorts were enrolled to analyze mortality at 30, 60, 180 and 65 days from the index date. Adjusted estimates were obtained with propensity score matching using the Greedy Nearest Neighbor Matching algorithm. Results We enrolled 34,625 individuals (67% females, mean age 82 years) distributed as follows: 30 days cohort, 4321 users vs 12,960 non-users; 60 days cohort, 4202 users vs 12,606 non-users; 180 days cohort, 3641 users vs 19,923 non-users; 365 days cohort, 2618 users vs 7854 non-users. Multivariate analyses showed a statistically significant excess mortality at 60, 180, and 365 days since the first prescription (HR: 1.83, HR: 1.63, and HR: 1.62, respectively). Conclusions This study showed that antipsychotics increase short- and long-term mortality risk in older adults with dementia. The prescription of AP should be carefully evaluated and, if it is the best option for patient and caregiver, stringently monitored. Key messages Antipsychotic medication use is associated with an increased all-cause mortality in elderly with dementia. The mortality risk increases in 60 days after starting their use and remains elevated at 1 year.

2018 ◽  
Vol 20 (12) ◽  
Author(s):  
Rajesh Gupta ◽  
Dylan D. Fortman ◽  
Daniel R. Morgenstern ◽  
Christopher J. Cooper

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Anirudh Kumar ◽  
Salim Virani ◽  
Scott Bassett ◽  
Mahboob Alam ◽  
Ravi Hira ◽  
...  

Background: Thrombocytopenia (TCP) occurs commonly in patients hospitalized with acute myocardial infarction (AMI). It is unclear whether persistent TCP after discharge among AMI survivors is associated with worse outcomes. Methods: We examined the impact of persistent post-discharge TCP on outcomes in a registry of consecutive AMI patients hospitalized between January 2004 and December 2007. In-hospital (IH) TCP was defined by a nadir platelet count < 150 x 109/L. Resolved TCP was defined as IH TCP which resolved within 3 months after discharge while persistent TCP was defined as IH TCP which did not resolve within 3 months. Results: Of 842 patients hospitalized for a first AMI, we examined data on 617 hospital survivors who had follow-up within 3 months of discharge and documented long-term outcomes. Of those, 474 (76.8%) patients did not experience IH TCP while 42 (6.8%) and 101 (16.4%) had persistent and resolved TCP, respectively (Table). Patients with persistent TCP were older, had worse comorbidities, and were more likely to have TCP at baseline and discharge. There were no inter-group differences in infarct size, major bleeding complications, revascularization, or ejection fraction at discharge. Mortality following discharge was higher at all time-points among AMI patients with persistent TCP compared to patients with resolved or without IH TCP (Figure). Patients with resolved TCP had comparable mortality to those without IH TCP. Conclusion: Persistent TCP within 3 months after hospital discharge for AMI is associated with significantly increased short- and long-term mortality compared to patients with recovered TCP or without IH TCP.


2014 ◽  
Vol 22 (4) ◽  
pp. 321-331 ◽  
Author(s):  
Ellen Melbye Langballe ◽  
Bo Engdahl ◽  
Hedvig Nordeng ◽  
Clive Ballard ◽  
Dag Aarsland ◽  
...  

2013 ◽  
Vol 28 (6) ◽  
pp. 947-953 ◽  
Author(s):  
Alexander Koch ◽  
Ralf Weiskirchen ◽  
Julian Kunze ◽  
Hanna Dückers ◽  
Jan Bruensing ◽  
...  

2011 ◽  
Vol 142 (5) ◽  
pp. 1052-1061 ◽  
Author(s):  
Vinod H. Thourani ◽  
W. Brent Keeling ◽  
Patrick D. Kilgo ◽  
John D. Puskas ◽  
Omar M. Lattouf ◽  
...  

2019 ◽  
Vol 74 (13) ◽  
pp. B673
Author(s):  
Thomas van den Boogert ◽  
Jetske Gunster ◽  
Martijn van Mourik ◽  
Jeroen Vendrik ◽  
Bimmer Claessen ◽  
...  

Cardiology ◽  
2016 ◽  
Vol 136 (1) ◽  
pp. 61-69 ◽  
Author(s):  
Xavier Rossello ◽  
Montserrat Vila ◽  
Mercedes Rivas-Lasarte ◽  
Andreu Ferrero-Gregori ◽  
Jordi Sans-Roselló ◽  
...  

Objectives: The impact of pulmonary artery catheterization (PAC) on survival in patients with cardiogenic shock (CS) is not well established. This study aimed to assess whether Swan-Ganz catheter monitoring is related to short- and long-term mortality in patients with CS. Methods: One hundred and twenty-nine consecutive patients with a first admission for CS were prospectively enrolled in a single-center registry between December 2005 and May 2009, and were subsequently followed up over 5.3 years. Results: PAC was used in 64% of all patients with a mean age of 68 years (65% men). After adjustment for age, gender and the presence of CS upon admission, PAC was associated with lower short-term mortality [hazard ratio (HR) = 0.55, 95% confidence interval (CI) 0.35-0.86, p = 0.008] as well as lower mortality rates in the long-term follow-up (HR = 0.63, 95% CI 0.41-0.97, p = 0.035). In a subgroup analysis, the use of PAC was associated with reduced mortality in patients without acute coronary syndrome (ACS), i.e. 49% in the Swan-Ganz group vs. 82% (p = 0.010), but there was no difference within the ACS group. Conclusions: The use of PAC in patients with CS was associated with lower short- and long-term mortality rates after adjustment for age, gender and the presence of shock upon admission. This benefit was only significant in those patients without ACS.


Sign in / Sign up

Export Citation Format

Share Document